WHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation.
Cell Experiment | |
---|---|
Cell lines | U87, U737 |
Preparation method | Seeding the cells into a 96-well plate at a density of 2.5×104 cells/well and incubating for 36 h at 37 ℃ before drug exposure. On the day of treatment, culture medium is carefully aspirated from the wells and replaced with fresh medium which contains the quinazoline compounds WHI-P154 at concentrations ranging from 0.1 μM to 250 μM. Using triplicate wells for each treatment. Incubating the cells with the compound for 24 hours to 36 hours at 37 ℃ in a humidified 5% CO2 atmosphere.10 μL of MTT (final concentration for each well, 0.5 mg/mL) is added, and the plate are incubated at 37 ℃ for 4 h. Than solubilized overnight at 37 ℃ in a solution containing 10% SDS in 0.01 M HCL. Mearsuring the absorbance of each well in a microplate reader at 570 nm. |
Concentrations | 0.1-250 μM |
Incubation time | 24-36 h |
Animal Experiment | |
---|---|
Animal models | SCID Xenograft Model of Human Glioblastoma (U737) |
Formulation | Dissolved in PBS |
Dosages | 0.5 mg/kg or 1 mg/kg for 10 days |
Administration | i.p. |
Molecular Weight | 376.2 |
Formula | C16H14BrN3O3 |
CAS Number | 211555-04-3 |
Solubility (25°C) | DMSO 60 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related JAK Products |
---|
A-005
A-005 is a potentially first-in-class, brain-penetrating TYK2 allosteric inhibitor for studies related to neuroinflammatory and neurodegenerative diseases. |
Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9)
Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide corresponding to amino acids 475 to 491 of mouse JAK2. |
JAK2/FLT3-IN-1 TFA
JAK2/FLT3-IN-1 (TFA) is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. |
ZT55
ZT55 is an orally active and highly-selective JAK2 inhibitor with an IC50 value of 0.031 μM. |
ZM39923
ZM39923 is a JAK3 inhibitor, with a pIC50 of 7.1; ZM39923 also potently inhibits tissue transglutaminase (TGM2) with an IC50 of 10 nM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.